Linagliptin: A Newly Approved Dipeptidyl Peptidase-4 Inhibitor for the Management of Type-2 Diabetes Mellitus

Nanjaian, Mahadevan and PAWAN, KRISHAN and PITCHAI, BALAKUMAR and NIDHI, SHARMA (2011) Linagliptin: A Newly Approved Dipeptidyl Peptidase-4 Inhibitor for the Management of Type-2 Diabetes Mellitus. International Journal of Recent Advances in Pharmaceutical Research, 3. pp. 11-14. ISSN 2230-9306


Download (71kB) | Preview


Diabetes mellitus is a metabolic disorder associated with deregulation of glucose metabolism due to lack of insulin secretion (Type-1 diabetes mellitus, T1DM) or deficient insulin secretion (Type-2 diabetes mellitus, T2DM). Studies suggest that T2DM often leads to serious complications including retinopathy, nephropathy, neuropathy and cardiomyopathy. The unsuccessful rate of diabetic control is persistently progressing in spite of effective treatment options available. It suggests the neediness of new therapeutic option to treat optimally the T2DM. Considerable number of studies demonstrated the potential of inhibitors of dipeptidyl peptidase-4 (DPP-4) in treating patients with T2DM. The first agent of this class, sitagliptin, was approved by the FDA in 2006, followed by vildagliptin (approved in 2008), saxagliptin (FDA approved in 2009) and linagliptin (FDA approved in 2011). DPP-4 inhibitors increase the levels of incretins such as glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP), which subsequently stimulate the release of insulin from pancreatic beta cells after a meal, resulting in better blood glucose control. The newly approved agent of DPP-4 class, linagliptin was demonstrated to be safe and effective in double-blind, placebo-controlled clinical studies involved about 3,800 T2DM patients. The present review discussed the therapeutic potentials of linagliptin for the management of T2DM.

Item Type: Article
Subjects: Pharmaceutical Sciences
Divisions: College of Pharmacy > Pharmacy
Date Deposited: 08 Jun 2017 10:48
Last Modified: 08 Jun 2017 10:48

Actions (login required)

View Item View Item